SHPK and ovarian cancer: Additionally, shikonin (SHK)-loaded, scFv78Fc-armed poly (lactic-co-glycolic acid) (PLGA) NPs, namely, scFv78Fc-PLGA-SHK NPs, were also effective for targeted therapy of solid tumors like ovarian cancer (Matthaiou et al., 2022).